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Abstract
During the last decade, nanomagnetic methods for delivering and targeting nucleic 
acids have been developed which are often referred to as magnetofection. Nucleic 
acids carry the building plans of living systems. As such, they can be exploited to 
make cells produce a desired protein, or to shut down the expression of endogenous 
genes or even to repair defective genes. Hence, nucleic acids are unique substances 
for research as well as therapy to exploit their potential, they need to be delivered 
into cells which can be a challenging task in many respects. Magnetofection provides 
a novel tool for high throughput gene screening in vitro and can help to overcome 
fundamental limitations to gene therapy in vivo. Magnetofection is nucleic acid 
delivery to cells, supported and site-specifically guided by the attractive forces of 
magnetic fields acting on nucleic acid shuttles (vectors) which are associated with 
magnetic nanoparticles. In a magnetofection procedure, self-assembling complexes of 
enhancers like cationic lipids with plasmid DNA and small interfering RNA (siRNA) 
are associated with magnetic nanoparticles and are then concentrated at the surface of 
cultured cells by applying a permanent inhomogeneous magnetic field.
Keywords: Magnetofection, Magnetic Nanoparticles, Nucleic Acid Therapy, 
Magnetic Drug Targeting.
1 INtRoDuctIoN
Magnetofection is defined as the magnetically enhanced delivery of nucleic acids associated with magnetic nanoparticles. Magnetofection is a novel, simple and highly efficient method to transfect cells 
in culture. This method attempts to unite the advantages of the popular 
biochemical (cationic lipids or polymers) and physical (electroporation, 
gene gun) transfection methods in single system while excluding their 
inconveniences including low efficiency and toxicity (Boussif et. al., 1995; 
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Cotton et. al., 1994). Magnetofection was invented by Christian Plank and 
Christian Bergemann and is registered as a trademark. It exploits magnetic 
force exerted upon gene vectors associated with magnetic particles to draw 
the vectors towards, possibly even into, the target cells. In this manner, the full 
vector dose applied gets concentrated on the cells within a few minutes so that 
100% of the cells get in contact with a significant vector dose (Hughes et. al., 
2001; Kanof et. al., 1999; Kasahara et. al., 1994).
1.1 Steps of Magnetofection Process
Magnetofection process used for enhanced delivery of biomolecules includes 
various steps such as:
Biomolecules, such as nucleic acids including plasmid DNA and siRNA, •	
are mixed with magnetic nanoparticles made of biodegradable iron oxides 
coated with cationic molecules in a simple one-step process to form a 
biomolecule / magnetic nanoparticle complex.
The biomolecule / magnetic nanoparticle complex is added to the cells to •	
be transfected in a standard multi-well plate.
A magnetic force is applied beneath the cells to be transfected using a •	
magnet array beneath the multi-well plate. This draws the biomolecule / 
magnetic nanoparticle complex onto cells on the bottom of the multi-well 
plate. The biomolecule is drawn towards, and delivered into, target cells, 
generally via endocytosis.
This leads to rapid, efficient transfection without disturbing membrane •	
architecture, causing chromosomal damage or leaving holes in cell 
membranes, therefore maintaining higher levels of cell viability. This is in 
stark contrast to physical transfection methods, including electroporation 
or biolistic methods, that can damage, create holes or electroshock the cell 
membranes causing cell death.
The magnetic nanoparticles are biodegradable and non-toxic at the •	
recommended doses.
After delivery into the cells, the biomolecules are released into the •	
cytoplasm by different mechanisms depending on the formulation used.
NanoTherics magnefect technology is unique in that the magnetic field 
created is designed to oscillate, which promotes more efficient uptake of the 
biomolecule into the cell and results in transfection efficiencies higher than 
other transfection techniques (Fouriki et. al., 2010; Hiemenz et. al., 2010; 
Finsinger et. al., 2000;)
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Figure 1: Principle of Magnetofection in Cell Culture (Schillinger et. al., 2005)
1.2 Principle of Magnetofection
The magnetofection principle is to associate nucleic acids with cationic 
magnetic nanoparticles. These molecular complexes are then concentrated and 
transported into cells supported by an appropriate magnetic field (Isner et. al., 
1996; Kru¨ger et. al., 1994). Polyelectrolyte-coated magnetic nanoparticles 
are mixed with naked nucleic acids or synthetic or viral nucleic acid vectors in 
salt-containing buffer. 
The particles associate with nucleic acids and vectors by electrostatic 
interaction and/or salt-induced colloid aggregation. The mixtures are added to 
cells in culture. The cell culture plate is positioned on a magnetic plate during 
5–30 min of incubation. The magnetic field (s) rapidly sediment vectors on the 
cells to be transfected/transduced. In this way, the magnetic force allows a very 
rapid concentration of the entire applied vector dose onto cells, so that 100% 
of the cells get in contact with a significant vector dose.
1.3 Mechanism of Magnetofection
The magnetic nanoparticles are made of iron oxide, which is fully 
biodegradable, coated with specific cationic proprietary molecules varying 
upon the applications. Their association with the gene vectors (DNA, 
siRNA, virus, etc.) is achieved by salt-induced colloidal aggregation and 
electrostatic interaction. The magnetic particles are then concentrated on 
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the target cells by the influence of an external magnetic field generated 
by magnets. The cellular uptake of the genetic material is accomplished 
by endocytosis and pinocytosis, two natural biological processes. 
Consequently, membrane architecture & structure stays intact, in contrast 
to other physical transfection methods that damage the cell membrane (Ma 
et. al., 2011; Fouriki et. al., 2010; Hiemenz et. al., 2010; Finsinger et. al., 
2000).
The nucleic acids are then released into the cytoplasm by different 
mechanisms depending upon the formulation used: 
1) Proton sponge effect caused by cationic polymers coated on the nanoparticles 
that promote endosome osmotic swelling, disruption of the endosom 
membrane and intracellular release of DNA form.
2) Destabilization of endosome by cationic lipids coated on the particles that 
release the nucleic acid into cells by flip-flop of cell negative lipids and 
charge neutralization.
3) Usual viral infection mechanism when virus is used. Magnetofection works 
for primary cells and hard to transfect cells that are not dividing or slowly 
dividing, meaning that the genetic materials can go to the cell nucleus 
without cell division. Coupling magnetic nanoparticles to gene vectors of 
any kind results in a dramatic increase of the uptake of these vectors and 
consequently high transfection efficiency.
4) Mechanism of oscillating nanomagnetic transfection
Figure 2: Proposed mechanism of oscillating nanomagnetic transfection 
(Fouriki et. al., 2010; Schillinger et. al., 2005)
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Plasmid DNA or siRNA is attached to magnet nanoparticles and incubated 
with cells in culture (left) (i) 
An oscillating magnet array below the surface of the cell culture plate pulls 
the particle into contact with the cell membrane (ii) and drags the particles 
from side-to-side across the cells, (iii) mechanically stimulating endocytosis 
(iv) Once the particle/DNA complex is endocytosed, proton sponge effects 
rupture the endosome (v) releasing the DNA (vi) which then transcribes the 
target protein.
1.4 technology: Magnetofection Reagents 
(Li et. al., 1999; Leon et. al., 1998; Leventis et. al., 1990)
As the manufacturer of the magnetofection technology, chemicell offers two 
types of ready-to-use Magnetofection reagents. 
PolyMAG is a universally applicable magnetic particle preparation for high 
efficiency nucleic acid delivery. It is mixed in a one-step procedure with the 
nucleic acid to be transfected and has been used successfully with plasmid 
DNA, antisense oligonucleotides and siRNAs. 
combiMAG is a magnetic particle preparation designed to be combined with 
any commercially available transfection reagent such as polycations and lipids 
and can be associated with plasmid DNA, antisense oligonucleotides, siRNAs 
or viruses. It allows you to create your own magnetic gene vector based on 
your favourite transfection reagent. 
1.5 Advantages of Magnetofection 
(Lu¨bbe et. al., 1998; Lu¨bbe et. al., 1996; Mendenhall et. al., 1996)
Greatly improved transfection rates in terms of percentage of cells transfected 
compared to standard transfection.
Up to several thousand fold increased levels of transgene expression •	
compared to standard transfections upon short-term incubation.
High transfection rates and transgene expression levels are achievable with •	
extremely low vector doses, which allow saving expensive transfection 
reagents. 
Extremely short process time. A few minutes of incubation of cells •	
with gene vectors are sufficient to generate high transfection efficiency, 
compared to several hours with standard procedures.
Magnet assisted transfection, or Magnetofection•	 TM, is a simple, highly 
effective method to transfect cells.
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It is an easy-to-use, fast and efficient technology that promotes the uptake •	
of biomolecules, such as nucleic acids including plasmid DNA and siRNA, 
into cells using magnetic nanoparticles and magnetic fields.
In cell culture, magnetic vectors are magnetically sedimented on the •	
target cells within minutes. Thus, the diffusion barrier to nucleic acid 
delivery is overcome, the full vector dose comes in contact with the 
target cells, and introduction of genetic material is synchronized.
Nucleic acid delivery is greatly accelerated and its efficiency with many, if •	
not most, vector types is improved. Magnetofection is applicable to small 
and large nucleic acids. 
Low-dose requirements, the possibility of confining nucleic acid •	
introduction to a localized area (magnetic targeting), and the amenability 
to high-throughput automation. Due to the favorable dose-response profile 
and the rapid kinetics, vector-related toxicity can be kept low. 
Magnetic nanoparticles for delivery of nucleic acid to target cells can use •	
either non-viral or viral vectors.
1.6 Applications of Magnetofection
This has several important consequences:
Magnetofection can be utilized to deliver synthetic siRNAs to cultured •	
cells. Certain magnetic nanomaterials associate with siRNAs and are 
suitable for siRNA delivery, either alone or in combination with cationic 
polymers or cationic lipid enhancers; these complexes are targeted to the 
Figure 3: Magnetic	nanomaterials	associated	with	DNA	(http://www.bocascientific.com)
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Figure 4:  Magnetofection for Virtal DNA transfection (www.chemicell.com; www.
ozbiosciences.com)
cell surface by application of a gradient magnetic field (Campbell et. al., 
2012; Mair et. al., 2009; Luo et. al., 2000)
Magnetofection is used for nucleic acid delivery by magnetic force acting •	
on magnetic particles and nucleic acids or nucleic acid vectors. Vectors 
are bound to magnetic, usually iron oxide, nanoparticles, in most cases by 
non-covalent bonds. Magnetic force accumulates and/or holds magnetic 
vectors in a target tissue against hydrodynamic forces (Mair et. al., 2009; 
Luo et. al., 2000; Widder et. al., 1983).
Magnetofection has been adapted to all types of nucleic acids (DNA, •	
siRNA, dsRNA, shRNA, mRNA, ODN), non-viral transfection systems 
(transfection reagents) and viruses. It has been successfully tested on a 
broad range of cell lines, hard-to-transfect and primary cells (Mykhaylyk 
et. al., 2008; Tomko et. al., 1997; Plank et. al., 1994).
Ocean NanoTech has developed superparamagnetic nanocrystals made •	
of iron oxide that are 5 nm to 50 nm in diameter that are ideal for 
magnetofection. The surfaces of the superparamagnetic nanocrystals 
are modified with biocompatible polymers with specific proprietary 
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anionic and cationic molecules that vary upon the applications. The 
superparamagnetic nanocrystals carrying the gene vectors are used to 
transfect the target cells through the influence of an external magnetic field. 
The cellular uptake of the genetic material is accomplished by two natural 
biological processes, endocytosis and pinocytosis, induced by the applied 
magnetic field. Use of the 5 or 10 nm superparamagnetic nanocrystals 
from Ocean NanoTech allows the membrane architecture & structure to 
remain intact unlike other bigger nanoparticles and physical transfection 
methods that damage the cell membrane. Small DNA sequences and 
plasmid are being introduced to the iron oxide nanocrystals which will 
subsequently be used to transfect specific cells (Pickles et. al., 2000; 
Meyer et. al., 1995; Wu et. al., 1987).
New magnetic technologies have been developed to improve the uptake •	
and expression of DNA and siRNA in cells growing in culture (Sukoyan 
et. al., 2013; Plank et. al., 2003; Plank et. al., 1999).
Gene vectors were associated with super-paramagnetic nanoparticles and •	
targeted gene delivery by application of a magnetic field. This potentiated 
the efficacy of any vector up to several hundred-fold, allowed reduction 
of the duration of gene delivery to minutes, extended the host tropism 
of adenoviral vectors to non-permissive cells and compensated for low 
retroviral titer (Scherer et. al., 2002; Povey et. al., 1986).
1.7 Biodistribution of magnetic nanoparticles
The biodegradable cationic magnetic nanoparticles are not-toxic at the •	
recommended doses and even at higher doses. Gene vectors / magnetic 
nanoparticles complexes are seen into cells after 10–15 minutes that is 
much faster than any other transfection method. After 24, 48 or 72 hours, 
most of the particles are localized in the cytoplasm, in vacuoles (membranes 
surrounded structure into cells) and occasionally in the nucleus (Plank et. 
al., 2011; Scherer et. al., 2002; Shayakhmetov et. al., 2000; Povey et. al., 
1986).
2 coNcluSIoN: FutuRe PeRSPectIveS oF 
MAGNetoFectIoN
A very exciting future perspectives of magnetofection is to use it therapeutically 
e.g. in tumor targeting or local neo-vessel formation. Apart from direct injection 
into the target tissue, the injection into blood vessels which are rather distant 
to the target site is assumed to become the most important form of vector 
administration for therapeutic magnetofection. 
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Iron oxide nanoparticles can be used as “superparamagnetic”, which means 
that they are strongly attracted to a magnetic field but they do not retain residual 
magnetism after the field is removed. Therefore they cannot agglomerate (like 
ferromagnetic particles) after removal of the magnetic field. It has been found 
that iron oxide particles used as contrast agents in magnetic resonance imaging 
(MRI) are fully biocompatible.
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